Ellahham S, Hausnerova E, Gottdiener J
Division of Cardiology, Washington Hospital Center, D.C. 20010, USA.
Clin Cardiol. 2000 Feb;23(2):91-5. doi: 10.1002/clc.4960230205.
Pulmonary vein spectral Doppler signals to characterize ventricular diastolic and systolic function, though often difficult to obtain, can be enhanced using contrast agents.
The objective of this study was to determine the efficacy of the intravenous contrast agent Optison for enhancement of Doppler signals in patients with poor signals on two-dimensional echocardiographic examinations.
Enhancement of pulmonary venous flow was evaluated in 191 patients at 0.2, 0.5, 3.0, and 5.0 ml per injection.
Greatest contrast enhancement for right and left pulmonary veins was observed at the highest doses. At 0.5 ml, conversion from inadequate to adequate was observed in right and left pulmonary veins in 48.0 and 79.3% of patients, respectively, while any degree of improvement was 54.4 and 65.8%, respectively. The adverse event rate (6.5%) was similar to a first-generation agent.
The results demonstrate that Optison is a safe and effective contrast agent for improving visualization of pulmonary Doppler signals, especially the left pulmonary vein.
肺静脉频谱多普勒信号用于表征心室舒张和收缩功能，尽管常常难以获取，但可使用造影剂予以增强。
本研究的目的是确定静脉注射造影剂Optison对二维超声心动图检查中信号不佳患者的多普勒信号增强效果。
对191例患者进行评估，每次注射0.2、0.5、3.0和5.0毫升造影剂后观察肺静脉血流的增强情况。
在最高剂量时观察到右肺静脉和左肺静脉的造影增强效果最佳。在0.5毫升剂量时，右肺静脉和左肺静脉分别有48.0%和79.3%的患者从不充分转变为充分，而有任何程度改善的分别为54.4%和65.8%。不良事件发生率（6.5%）与第一代造影剂相似。
结果表明，Optison是一种安全有效的造影剂，可改善肺多普勒信号的可视化，尤其是左肺静脉。
